Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21505399 | 0.78 | METAP1 (0.39) | MEN1KMT2AMAPTCA2ALDH1A1 | |
| SCHEMBL10048462 | 0.76 | ELANE (0.40) | ELANEMEN1KMT2ACA2 | |
| SCHEMBL23704812 | 0.73 | SLC6A4 (0.36) | MEN1KMT2AALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL10048463 | 0.71 | ELANE (0.42) | ELANEMEN1KMT2ACA2 | |
| SCHEMBL10046125 | 0.71 | ELANE (0.42) | ELANEMEN1KMT2ACA2 | |
| SCHEMBL10483703 | 0.69 | ELANE (0.56) | ELANEMEN1KMT2AMAPTCA2 | |
| SCHEMBL31064525 | 0.67 | METAP1 (0.38) | MAPTALDH1A1 | |
| SCHEMBL11735810 | 0.67 | MAOA (0.54) | ELANEMEN1KMT2A | |
| SCHEMBL19132617 | 0.67 | MAOA (0.50) | ELANEMEN1KMT2A | |
| SCHEMBL31554124 | 0.66 | KMT2A (0.40) | KMT2AMAPTCA2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173678-B2 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872023-B2 | administering 6-Hydroxy-1,2,3,4-tetrahydro-naphthalene-2(-)-carboxylic acid{1-[4-(3-hydroxyphenyl)-(3R)-(4R)-trans-dimethyl-piperidinylmethyl]-(2S)-methylpropyl}-amide, for the treatment of drug abuse and dependence | RESEARCH TRIANGLE INSTITUTE (US) | 2011-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065743-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | ELANE 2228/4885MEN1 4885/4885KMT2A 2276/4885 |
| US-20120178781-A1 | KAPPA OPIOID RECEPTOR LIGANDS | OPRK1, OPRD1, OPRM1 | ELANE 2228/4885MEN1 4885/4885KMT2A 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.